CHRISTOPHER PAGNANI: Open Payments
NPI 1215172374 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,497 in 72 payments from 20 companies in 2025. Trend: 2023 $891 · 2024 $984 · 2025 $1,497
Food & beverage: $1,497
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $175 |
| Alkermes, Inc. | 7 | $152 |
| Vanda Pharmaceuticals Inc. | 7 | $129 |
| Tris Pharma Inc | 5 | $103 |
| Neos Therapeutics, LP | 6 | $101 |
| Supernus Pharmaceuticals, Inc. | 4 | $101 |
| Lundbeck LLC | 4 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $99 |
| ABBVIE INC. | 4 | $84 |
| Collegium Pharmaceutical, Inc. | 3 | $67 |
Products named: CAPLYTA, FANAPT, Dyanavel XR, Adzenys XR-ODT, Qelbree, REXULTI, TRINTELLIX, LYBALVI.
Industry payments across PA — which companies pay providers there.
